Leclaza (Lazertinib)
EGFR T790M-mutated Non-Small Cell Lung Cancer (NSCLC)
Key Facts
Indication
EGFR T790M-mutated Non-Small Cell Lung Cancer (NSCLC)
Phase
Approved
Status
Commercial/Phase 3 Global
Company
About Yuhan
Founded in 1926, Yuhan Corporation is one of South Korea's most established and innovative pharmaceutical companies, operating with a dual focus on a profitable commercial business and a cutting-edge R&D pipeline. The company has achieved significant milestones, including the successful development and out-licensing of its EGFR inhibitor, lazertinib, to Janssen, and the commercialization of its leading diabetes franchise. Yuhan's strategy is built on internal R&D in oncology and immunology, strategic in-licensing, and global partnerships to expand its reach beyond the Korean market.
View full company profile